Predictive Biomarkers and Targeted Therapies in Adult Brain Cancers

  • Jose M. BonninEmail author


Diffuse glial neoplasms in adults remain incurable, with high morbidity and mortality, despite significant advances in our understanding of their molecular characteristics and the underlying alterations in specific signaling pathways. With rare exceptions, and unlike the successes in treatment of other solid tumors, successful application of targeted therapies for glial neoplasms has remained elusive. Mutations in the IDH1/2 genes are factors in the neoplastic transformation of a large proportion of intermediate and high-grade gliomas, and a variety of treatment approaches including the development of vaccines and molecular inhibitors are currently being evaluated. Epigenetic factors such as DNA methylation also play an important role in the response to specific therapies. The accurate screening of predictive biomarkers in the diagnosis of gliomas and other tumors of the nervous system is now needed to allow selection of the most appropriate therapeutic approaches based on the molecular characteristics of the tumor.


IDH-mutant High-grade glioma Low-grade glioma Glioblastoma MGMT promoter methylation 1p19q codeletion Oligodendroglioma Ependymomas C11orf95-RELA fusion BRAF mutations Temozolamide KIAA1549–BRAF fusion Angiogenesis Pleomorphic xanthoastrocytoma BRAF-V600E 


  1. 1.
    Cagney DN, Sul J, Huang RY, et al. The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. Neuro-Oncology. 2017; Scholar
  2. 2.
    Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.CrossRefGoogle Scholar
  3. 3.
    Velazquez Vega JE, Brat DJ. Incorporating advances in molecular pathology into brain tumor diagnostics. Adv Anat Pathol. 2018;25:143.PubMedGoogle Scholar
  4. 4.
    Staedtke V, a Dzaye OD, Holdhoff M. Actionable molecular biomarkers in primary brain tumors. Trends Cancer. 2016;2:338–49.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, et al. Advances in the molecular genetics of gliomas – implications for classification and therapy. Nat Rev Clin Oncol. 2017;14:434–52.CrossRefPubMedGoogle Scholar
  6. 6.
    Ballester LY, Fuller GN, Powell SZ, et al. Retrospective analysis of molecular and immunohistochemical characterization of 381 primary brain tumors. J Neuropathol Exp Neurol. 2017;76:179–88.PubMedGoogle Scholar
  7. 7.
    Khan IN, Ullah N, Hussein D, et al. Current and emerging biomarkers in tumors of the central nervous system: possible diagnostic, prognostic and therapeutic applications. Semin Cancer Biol. 2017;17:30114–1.Google Scholar
  8. 8.
    Chen R, Cohen AL, Colman H. Targeted therapeutics in patients with high-grade gliomas: past, present, and future. Curr Treat Options in Oncol. 2016;17:42.CrossRefGoogle Scholar
  9. 9.
    Lieberman F. Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials. F1000Res. 2017;6:1892.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Johanns TM, Dunn GP. Applied cancer immunogenomics: leveraging neoantigen discovery in glioblastoma. Cancer J. 2017;23:125–30.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Diamandis P, Aldape KD. Insights from molecular profiling of adult glioma. J Clin Oncol. 2017;35:2386–93.CrossRefPubMedGoogle Scholar
  12. 12.
    Collins VP, Jones DT, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 2015;129:775–88.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pajtler KW, Mack SC, Ramaswamy V, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 2017;133:5–12.CrossRefPubMedGoogle Scholar
  14. 14.
    Mack SC, Pajtler KW, Chavez L, et al. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. 2018;553:101–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Kickingereder P, et al. IDH mutation status is associated with a distinct hypoxia angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep. 2015;5:16238.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory MedicineIndiana University School of MedicineIndianapolisUSA

Personalised recommendations